Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Hormone Replacement Therapy
Design flaws may have been source of adverse conclusions in Women's Health Initiative study
February 23rd, 2006
Design flaws have been proposed as the reason for the adverse conclusions that were drawn from the Women's Health Initiative study. Scientists at the University of Massachusetts conducted a review that "critiques the Women's Health Initiative (WHI) study, focusing on aspects of the study design contributing to the adverse events resulting in the study's discontinuation." E.L. Klaiber and colleagues wrote, "Two aspects of the design contributed to the adverse events: [1] The decision to administer continuous combined conjugated equine estrogen (CEE)/medroxyprogesterone acetate (MPA) or E alone as a standard regimen to a population...
Source: Women's Health Weekly (2006-02-23)
|
